Accretion Nutraveda Ltd. (ANL) Share Price Within 2% of 52-Week High

Accretion Nutraveda Ltd. traded at Rs 303.5 and remained within 2% of its 52-week high. The company’s market capitalisation stood at Rs 219.73 crore.

Accretion Nutraveda Ltd. Share Price was at Rs 303.5 at the time of this Univest update, placing the stock within 2% of its 52-week high and taking its market capitalisation to Rs 219.73 crore. That proximity to a one-year peak is notable because it often draws attention from traders tracking relative strength and from investors comparing valuation and profitability against industry peers.

The verified data confirms the price event at 07 August 2026 at 4:26:08 PM IST, with the event-qualified last traded price recorded at Rs 303.5. While the supplied data establishes that the stock is trading close to its yearly high, it does not establish a company-specific catalyst for the move. That makes the broader context especially important.

For Accretion Nutraveda Ltd. Share Price Today, the current setup matters for more than short-term interest. The company trades in the Healthcare sector under Pharmaceuticals & Drugs, and its reported valuation and return metrics stand meaningfully above several industry benchmarks. Univest data therefore suggests that the stock is attracting attention not only because of price proximity to a 52-week high, but also because of how its fundamentals compare with the same-industry universe.

Accretion Nutraveda Ltd. Share Price Today: Within 2% of 52-Week High

Metric	Value
LTP at 2% Qualification	Rs 303.5
Market Capitalisation	Rs 219.73 crore
52-Week High Position	Trading within 2% of its 52-week high

Accretion Nutraveda Ltd. (ANL) traded at Rs 303.5. Reported volume was 7,000.

Accretion Nutraveda Ltd. Share Price Today stood at Rs 303.5, and the Univest screener identified the stock as trading within 2% of its 52-week high. The event-qualified last traded price was also Rs 303.5, which confirms that the stock was screened near its one-year peak at the time of qualification on 07 August 2026 at 4:26:08 PM IST.

Even without a full intraday dataset such as previous close, open, high, low or turnover in the supplied feed, the proximity itself is meaningful. Stocks trading close to their yearly highs often move into focus because market participants use this zone to judge whether momentum is holding up and whether valuation still appears justified against sector and peer numbers. In this case, Accretion Nutraveda Ltd. Share Price is being watched alongside a market capitalisation of Rs 219.73 crore, placing it near the same-industry median market capitalisation of Rs 144.13 crore but below the same-industry average of Rs 502.55 crore.

That combination can matter. A small-cap Healthcare stock nearing its one-year high may attract fresh screening interest when it also shows stronger-than-median return ratios or premium valuation multiples. Here, the headline price event is clear, but the next step is to check whether the fundamentals and comparative metrics support why the stock is appearing on screeners and in Accretion Nutraveda Ltd. Stock News discussions on Univest.

Accretion Nutraveda Ltd. (ANL) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 219.73 crore
P/E Ratio	43.35x
P/B Ratio	6.19x
ROE	106.65%
ROCE	21.4%
EPS	Rs 7
Book Value Per Share	Rs 49
Dividend Yield	0%

Accretion Nutraveda Ltd. was valued at a P/E ratio of 43.35x, a P/B ratio of 6.19x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of 106.65% and ROCE of 21.4%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Per-share and shareholder-return metrics included EPS of Rs 7, book value per share of Rs 49, dividend yield of 0%. Dividend yield is a current or historical ratio and does not guarantee future distributions.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Industry	Pharmaceuticals & Drugs
Benchmark Scope	same industry
Company P/E Ratio	43.35x
Benchmark Median P/E	18.6x
Benchmark Average P/E	62x
Benchmark P/E Range	0x to 3,493.04x
Company P/B Ratio	6.19x
Benchmark Median P/B	1.83x
Company ROE	106.65%
Benchmark Median ROE	10.21%
Company ROCE	21.4%
Benchmark Median ROCE	12.96%
Company Market Capitalisation	Rs 219.73 crore
Benchmark Median Market Cap	Rs 144.13 crore

Accretion Nutraveda Ltd. (ANL) is classified under sector: Healthcare and industry: Pharmaceuticals & Drugs.

Accretion Nutraveda Ltd. (ANL) has a P/E ratio of 43.35x, which is above the benchmark median of 18.6x, a difference of +133.06%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

Accretion Nutraveda Ltd. (ANL) has a ROE of 106.65%, which is above the benchmark median of 10.21%, a difference of +944.56%. Accretion Nutraveda Ltd. (ANL) has a ROCE of 21.4%, which is above the benchmark median of 12.96%, a difference of +65.12%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Gennex Laboratories Ltd.	GENNE	216.22	10.46	0.99	10.71	13.24
Sanjivani Paranteral Ltd.	SANJIVIN	235.24	36.68	5.16	0	266.43
Accretion Pharmaceuticals Ltd.	ACCPL-ST	199.92	20.68	3.83	27.18	12.62
Coral Laboratories Ltd.	CORALAB	199.35	12.17	0.95	10.74	13.35
BIO MEDICA LABORATORIES L	BMLL-SM	188.69	16.17	10.41	13.67	10.17

Accretion Nutraveda Ltd. (ANL) has a P/E ratio of 43.35x compared with the displayed peer median of 16.17x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of 106.65% compares with a peer median of 10.74% across the companies shown in the table. ROCE stood at 21.4% versus the displayed peer median of 13.24%, providing a capital-efficiency comparison. Accretion Nutraveda Ltd. (ANL) has a market capitalisation of Rs 219.73 crore. Among the 5 peers shown, 1 have a larger market capitalisation.

Why Investors Are Watching Accretion Nutraveda Ltd.

• The stock is trading at Rs 303.5 and remains within 2% of its 52-week high, which naturally puts Accretion Nutraveda Ltd. Share Price on momentum and breakout watchlists.
• The company’s market capitalisation is Rs 219.73 crore, above the same-industry median of Rs 144.13 crore but below the average of Rs 502.55 crore.
• Valuation is elevated versus industry medians, with P/E at 43.35 against 18.6 and P/B at 6.19 against 1.83.
• Reported profitability is strong relative to the benchmark, with ROE at 106.65% and ROCE at 21.4.
• Peer comparison shows the stock trades at a premium to several similarly sized Pharmaceuticals & Drugs companies.
• The Healthcare and same-industry benchmark context supplied by Univest makes the price move easier to frame against comparable listed companies.

About Accretion Nutraveda Ltd.

Accretion Nutraveda Ltd. is classified in the Healthcare sector and the Pharmaceuticals & Drugs industry. That places the company within a listed universe where valuation, return ratios and market-cap positioning are often compared against a broad group of healthcare and pharmaceutical businesses.

Based on the supplied company context, the most reliable way to frame Accretion Nutraveda Ltd. is through its market classification and financial profile rather than through unsupported operational detail. The stock is part of a same-industry benchmark set of 136 companies and a broader same-sector universe of 197 companies. Within that listed space, Accretion Nutraveda Ltd. stands out for a market capitalisation of Rs 219.73 crore, a P/E of 43.35, a P/B of 6.19, ROE of 106.65% and ROCE of 21.4. For readers tracking Accretion Nutraveda Ltd. Stock News, that means the company is currently being evaluated not only as a Healthcare name but also as a Pharmaceuticals & Drugs stock with premium valuation and strong reported return metrics.

Track Accretion Nutraveda Ltd. Share Price on Univest

Use Accretion Nutraveda Ltd. (ANL) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors tracking Accretion Nutraveda Ltd. Share Price can use Univest to follow live price movement, 52-week levels, technical indicators, valuation ratios, profitability metrics, sector comparisons, peer snapshots and shareholding data when updated. For a stock currently trading within 2% of its 52-week high, that kind of consolidated view can help users monitor how price action aligns with fundamentals and industry positioning.

Accretion Nutraveda Ltd. Share Price Today is one data point, but the wider context matters as well. On Univest, users can track whether valuation remains above peer medians, how the company compares with other Healthcare and Pharmaceuticals & Drugs names, and whether future updates change the balance between market pricing and financial metrics.

Frequently Asked Questions

What is Accretion Nutraveda Ltd. Share Price today?

Ans. Accretion Nutraveda Ltd. Share Price was Rs 303.5 at the time of the screened event on 07 August 2026 at 4:26:08 PM IST. That price also matched the event-qualified last traded price used in the Univest update.

Why is Accretion Nutraveda Ltd. Share Price in focus today?

Ans. The stock is in focus because Univest identified it as trading within 2% of its 52-week high. For a Rs 219.73 crore company, that price position often brings added attention to valuation and peer comparisons.

What is the market capitalisation of Accretion Nutraveda Ltd.?

Ans. Accretion Nutraveda Ltd. had a market capitalisation of Rs 219.73 crore in the supplied dataset. That is above the same-industry median of Rs 144.13 crore, though still below the same-industry average of Rs 502.55 crore.

How is Accretion Nutraveda Ltd. valued on P/E and P/B?

Ans. The company trades at a P/E ratio of 43.35 and a P/B ratio of 6.19. Both are above the same-industry medians of 18.6 and 1.83, indicating a premium valuation against many comparable listed companies.

What do the profitability ratios show for Accretion Nutraveda Ltd.?

Ans. The reported ROE is 106.65% and ROCE is 21.4. Both metrics are above the same-industry medians of 10.21 and 12.96, suggesting stronger reported returns than a large part of the benchmark universe.

Which sector and industry does Accretion Nutraveda Ltd. belong to?

Ans. Accretion Nutraveda Ltd. belongs to the Healthcare sector and the Pharmaceuticals & Drugs industry. The same-industry benchmark in the supplied dataset covers 136 companies, while the broader same-sector universe contains 197 companies.

How does Accretion Nutraveda Ltd. compare with selected peers?

Ans. Compared with peers such as Gennex Laboratories, Sanjivani Paranteral, Accretion Pharmaceuticals, Coral Laboratories and BIO MEDICA LABORATORIES L, the company carries a higher P/E than most while showing notably stronger ROE on the supplied figures.